MARATTO

article · The Lancet Global Health

Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018–22: an observational cohort study

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

The South African Medical Research Council, the European and Developing Countries Clinical Trials Partnership, and the National Research Foundation.

Research topics

  • Antimicrobial Resistance in Staphylococcus
  • Tuberculosis Research and Epidemiology
  • Pharmacovigilance and Adverse Drug Reactions

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/s2214-109x(25)00489-9

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.